Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers

被引：20
|
作者：
Özdemir, V [1 ]
Tyndale, RF
Reed, K
Herrmann, N
Sellers, EM
Kalow, W
Naranjo, CA
机构：
[1] Univ Toronto, Dept Pharmacol, Toronto, ON M4N 3M5, Canada
[2] Univ Toronto, Sunnybrook Hlth Sci Ctr, Psychopharmacol Res Program, Toronto, ON M4N 3M5, Canada
[3] Univ Toronto, Womens Coll Hosp, Psychopharmacol & Dependence Res Unit, Toronto, ON M4N 3M5, Canada
[4] Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M4N 3M5, Canada
[5] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON M4N 3M5, Canada
[6] Univ Toronto, Dept Psychiat, Toronto, ON M4N 3M5, Canada
[7] Univ Toronto, Dept Med, Toronto, ON M4N 3M5, Canada
来源：
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | 1999年 / 19卷 / 05期
关键词：
D O I：
10.1097/00004714-199910000-00014
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：472 / 475
页数：4
相关论文
共 50 条
  • [41] Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites-a study in 839 patients with known CYP2D6 genotype
    Wollmann, Birgit M.
    Storset, Elisabet
    Kringen, Marianne Kristiansen
    Molden, Espen
    Smith, Robert L.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (04) : 523 - 531
  • [42] Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol
    Linnet, K
    Wiborg, O
    THERAPEUTIC DRUG MONITORING, 1996, 18 (06) : 629 - 634
  • [43] Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite
    Suzuki, A
    Otani, K
    Mihara, K
    Yasui, N
    Kondo, T
    Tokinaga, N
    Furukori, H
    Kaneko, S
    Inoue, Y
    Hayashi, K
    PSYCHOPHARMACOLOGY, 1998, 135 (04) : 333 - 337
  • [44] Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite
    A. Suzuki
    K. Otani
    K. Mihara
    N. Yasui
    T. Kondo
    N. Tokinaga
    H. Furukori
    S. Kaneko
    Y. Inoue
    K. Hayashi
    Psychopharmacology, 1998, 135 : 333 - 337
  • [45] POOR METABOLIZERS OF NICOTINE AND CYP2D6 POLYMORPHISM
    CHOLERTON, S
    ARPANAHI, A
    MCCRACKEN, N
    BOUSTEAD, C
    TABER, H
    JOHNSTONE, E
    LEATHART, J
    DALY, AK
    IDLE, JR
    LANCET, 1994, 343 (8888): : 62 - 63
  • [46] Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers
    Chen, Yingxue
    Zhou, Diansong
    Tang, Weifeng
    Zhou, Wangda
    Al-Huniti, Nidal
    Masson, Eric
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (04): : 485 - 493
  • [47] Effect of CYP2D6 genotype on duloxetine serum concentration
    Hole, Kristine
    Gangso, Sofie
    Jensstuen, Asa Tonette
    Ormoy, Hanne Holte
    Paulsen, Maren
    Molden, Espen
    Haslemo, Tore
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2024, 134 (01) : 186 - 192
  • [48] Pharmacokinetics of Oxycodone in Extensive and Poor Metabolizers of CYP2D6 during Cotreatment with Placebo or Quinidine
    Sirhan-Daneau, Andrea
    Michaud, Veronique
    St-Onge, Maude
    Turgeon, Jacques
    DRUG METABOLISM REVIEWS, 2009, 41 : 81 - 82
  • [49] Gender differences and intrasubject variability in CYP2D6 activity in extensive metabolizers of dextromethorphan (DM).
    Decker, J
    Lindley, C
    Williamson, K
    McCune, J
    Graff, D
    Carson, S
    Pieper, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 215 - 215
  • [50] Catalytic in vivo function of CYP2D6 in relation to the genotype
    Griese, EU
    Gaedigk, A
    Morike
    Mikus, G
    Zanger, U
    Eichelbaum, M
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 355 (04) : 458 - 458
12345